Literature DB >> 35231828

Effect of ACY-1215 on cytoskeletal remodeling and histone acetylation in bovine somatic cell nuclear transfer embryos.

Song Gao1, Zheng Wang1, Jukui Ma1, Jingyi Wang2, Xupeng Xing3, Chenglong Shen1, Zhihan Niu1, Heqiang Li1, Shaowei Zhang1, Kaijuan Zhang1, Jing Gao1, Yong Zhang4, Yongsheng Wang5.   

Abstract

The latest studies indicated that in addition to alterations in abnormal chromosome epigenetic modifications, the abnormal cytoskeletal changes are also an important cause for the developmental failure of somatic cell nuclear transfer (SCNT) embryos. In the present study, the effects of ACY-1215, a specific inhibitor of HDAC6, on the acetylation of α-tubulin, histone epigenetic modification, spindle formation and embryonic development of early bovine SCNT embryos were studied. The results showed that acetylation of α-tubulin, H3K9, and H4K16 was significantly lower in SCNT embryos than in vitro fertilization (IVF) embryos. After ACY-1215 treatment, the acetylation level of α-tubulin, H3K9, and H4K16 of SCNT embryos was closer to that of IVF embryos. ACY-1215 treatment reduced spindle abnormalities, delayed the time of first cleavage of embryos, increased the total cell number and trophectoderm cells numbers, and reduced apoptosis in SCNT blastocysts. ACY-1215 regulated the process of embryonic epigenetic modification and cytoskeletal protein acetylation, corrected abnormal development of SCNT embryos, and improved SCNT embryonic development potential.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Acetylated α-tubulin; Bovine; Histone acetylation modification; SCNT embryo

Mesh:

Substances:

Year:  2022        PMID: 35231828     DOI: 10.1016/j.theriogenology.2022.02.018

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  1 in total

Review 1.  Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases.

Authors:  Jianglei Li; Meihong Yu; Shifeng Fu; Deliang Liu; Yuyong Tan
Journal:  Front Pharmacol       Date:  2022-05-16       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.